May Awards — August 2010
Adinoff, Bryon, NIH, Impulsivity, Neural Deficits, and Cocaine Relapse, $299,334; Bachoo, Robert, NIH, Genetic Dissection of Glioblastoma: Cell of Origin, $360,388; Blount, Paul, NASA, Modifying Protein-Lipid Interactions of Microbial Mechanosensitive Channel, $124,912; Blount, Paul, NIH, High Throughput Screening: Bacterial Mechanosensitive Channels as Drug Targets — ARRA Stimulus Funding, $78,500; Boothman, David (X. Luo, fellow), Dept. of Defense, Stress-Induced Premature Senescence Promotes Prostate Cancer Growth and Metastasis Through Alteration of Microenvironment, $62,100.
Brandon, Anna, NIH, Partner-Assisted Therapy for Treatment of Depression in Pregnancy, $128,386; Brown, E. Sherwood, NIH, Quetiapine for Bipolar Disorder and Alcohol Dependence, $279,775; Brown, E. Sherwood, NIH, Quetiapine for Bipolar Disorder and Alcohol Dependence — Admin. Supplement, $8,869; Bruick, Richard, NIH, Regulation of Hypoxia Inducible Factor (HIF), $243,534; Byerly, Matthew, NIH/Univ. of North Carolina-Chapel Hill, CATIE: Metformin in Treatment of Antipsychotic-Induced Weight Gain in Schizophrenia, $8,690.
Conrad, Nicholas, NIH, Mechanisms of KSHV Post-Transcriptional Gene Regulation, $314,000; Cullum, C. Munro, NIH, Telecognitive Assessment: Extending Neuropsychology to Underserved Elders, $254,905; Cullum, C. Munro, NIH/Baylor Coll. of Medicine, Adult Neurobehavioral Late Effects of Pediatric Low Grade Brain Tumors (Patient Reimbursement), $6,967; Drazner, Mark, NIH/New England Research Inst., TOPCAT: Treatment of Preserved Cardiac Function Heart Failure With Aldosterone Antagonist, $1,850; Eisch, Amelia, NIH, Opiates and Adult Neurogenesis — Diversity Supplement, $30,908.
Elmquist, Joel, NIH, CNS Pathways Regulating Ghrelin Effects on Body Weight, $345,832; Falck, J. Russell, NIH/Medical Coll. of Wisconsin, Microvascular O2 Responses in Salt Sensitive Hypertension, $19,905; Fitz, J. Gregory, NIH, Regulation of Secretion by Bile Duct Epithelial Cells, $349,718; Forman, James, NIH, Immune Potential of Animals Lacking Class IA Molecules, $30,043; Gao, Jinming, NIH, UltraSensitive MR Probes for Molecular Diagnosis of Lung Cancer, $325,775.
Goodman, Joel, NIH, Simple Cellular Model for Lipodystrophy, $310,860; Graff, Jonathan, NIH, Adipocyte Development: Lineage Analysis and Molecular Characterization, $388,575; Grinnell, Frederick, NIH/Purdue Univ., Cryopreservation of Functional Engineered Tissues, $55,819; Gumbo, Tawanda, NIH, PKPD of Combination Anti-tuberculosis Therapy for Suppression of Drug Resistance, $601,501.
Halvorson, Lisa, NIH, Pituitary PACAP Gene Regulation by Hypothalamic, Pituitary and Gonadal Factors, $252,853; Hobbs, Helen, NIH, Expression Profiling of Cellular Metabolism Using Massively Parallel Sequencing — ARRA Stimulus Equipment Funds, $493,756; Hodics, Timea, NIH, TDCS-Enhanced Stroke Recovery and Cortical Reorganization, $162,324; Hofmann, Sandra, NIH, Molecular Basis of Infantile NCL, $338,635; Hooper, Lora (B. Duerkop, fellow), NIH, Interactions of Commensal Bacterium With Intestinal Mucosal Surface, $47,606.
Hsieh, Jer-Tsong, Dept. of Defense, Suppression of BRCA2 by Mutant Mitochondrial DNA in Prostate Cancer, $239,769; Hutchison, Michele, NIH, Examination of Pre-Pubertal Mammalian Growth Plate, $122,596; Huth, James, NIH/John Wayne Cancer Inst., Prospective Study of Natural History of MMAIT34 Patients; MMAIT Follow-Up Study, $750; Idris, Ahamed, NIH/Univ. of Washington, Hypertonic Resuscitation Following Traumatic Injury, $258,375; Janowski, Bethany, NIH, Molecular Switches: Regulatory RNAs Targeting Nuclear Hormone Receptor Promoters, $248,688.
Jiang, Jin, NIH, Complex Regulation of Ci-Gli Proteins in Hedgehog Signal Transduction, $326,403; Jiang, QiuXing, NIH, Structural Study of a Kv Channel in Different Conformations in Membranes, $301,150; Johnson, Mark, NIH/Univ. of British Columbia, Secondary Prevention of Small Subcortical Strokes (SPS3), $16,000; Khera, Amit, NIH/Yale Univ., Young Women With Acute Myocardial Infarction (VIRGO), $2,000; Kovacs, Zoltan, NIH, Hyperpolarized 89Y Complexes as Potential In Vivo Imaging Agents, $194,288.
Levine, Benjamin, National Space Biomedical Research Inst., Team Leader for Cardiovascular Alterations Team, $80,000; Levine, Beth, NIH, Infectious Diseases Training Program, $115,293; Li, Quanzhen, NIH, Tissue Kallikrein in Immune Mediated Nephritis — ARRA Stimulus 2 Yr Resub, $78,500; Liu, ZhiPing, NIH, Role of FOXO4 in Atherosclerosis, $343,006; Lu, Christopher, NIH, TLR4 and Murine Ischemic Acute Renal Failure, $303,203.
Lu, Hanzhang, NIH, Modulation of Brain Activity by Control of Inspired Air, $389,484; Mason, Ralph, NIH, UT Southwestern Small Animal Imaging Resource (MPI), $4,377; McClung, Colleen, NIH, Addiction-Like Behavior in Models of Mood Disorders: Role of CLOCK and NPAS2, $388,575; Moe, Orson, NIH, Generation of High Impact Resources for Erythropoietin Receptor Research, $230,652; Niederkorn, Jerry, NIH, Immunological Modulation of Ocular Tumor Metastases, $287,239.
Nirodi, Chaitanya, NIH, Role of EGFR in DNA Repair and Radiation Response in Non-Small-Cell Lung Cancer, $260,620; Okada, Pamela, NIH/Children’s Research Inst., Lorazepam Efficacy and Safety Study, $158,500; Olson, Eric, NIH, MicroRNA Control of Cardiac Gene Expression, Function and Disease, $538,510; Olson, Eric, NIH, Genetic Dissection of Cardiogenesis, $517,235; Olson, Eric (D. Quiat, fellow), NIH, Role of miR210 in Cardiomyocyte Metabolism Following Myocardial Infarction, $27,780.
OrthTaussig, Kimberly, NIH, Biochemical Characterization of Yersinia Effector YpoJ, $28,260; O’Suilleabhain, Padraig, NIH/Massachusetts General Hosp., Coenzyme Q10 in Huntington’s Disease, $7,910; Otwinowski, Zbyszek, NIH, Crystallography of Macromolecules, $478,516; Pandita, Tej, NIH, Chromatin Modifying Factor Control Radiation Response and Genomic Stability, $315,400; Patel, Ashish, NIH/CedarsSinai Med. Ctr., Role of GWAS Identified Variants as Predictors of Outcome to Anti-TNFa Therapy in Pediatric Inflammatory Bowel Disease, $11,025.
Peterson, Gail, NIH/Johns Hopkins Univ., Endogenous Cardiac Glycosides in Development of Cardiovascular Disease in African-Americans with Hypertensive Kidney Disease — ARRA Stimulus Funding, $35,515; Phelps, Katherine, NIH, In Vivo Multiphoton Microscope for UT Southwestern Live Cell Imaging Facility — ARRA Stimulus High End Inst, $1,190,132; Quinn, Charles, NIH/Washington Univ. in St. Louis, Silent Cerebral Infarct MultiCenter Clinical Trial, $2,175; Raskin, Philip, NIH, Pioglitazone Preserves Insulin Secretion in Type 1 Diabetes, $662,001; Repa, Joyce, NIH, Nuclear Hormone Receptor Regulation of Cholesterol Absorption, $310,860.
Rockey, Don, NIH, Nitric Oxide and Cellular Pathogenesis of Portal Hypertension, $373,032; Roth, Michael (N. Satterly, fellow), NIH, Molecular Basis for Erlotinib Resistance in Lung Cancer with Wild-Type EGFR, $47,606; Rothermel, Beverly, NIH, Modulating Calcineurin Signaling Pathways in Muscle, $392,500; Sakhaee, Khashayar, NIH, Pathogenesis of Idiopathic Uric Acid Nephrolithiasis: Role of Renal Lipotoxicity, $373,032; Scaglioni, Pier, NIH, Characterization and Drug Targeting of PML Tumor Suppressor in Lung Cancer — ARRA Stimulus Funding, $325,775.
Scheuermann, Richard, NIH/Northrop Grumman Corp., Bioinformatics Resource Center for Infectious Diseases (BRC), $544,857; Shaul, Philip, NIH, Oxysterols, Estrogen Receptor Antagonism and Vascular Disease, $392,500; Skinner, Celette, NIH, Facilitating Risk-Appropriate Colorectal Cancer Testing, $267,963; Sperandio, Vanessa, NIH, Quorum Sensing Regulation of EHEC Virulence Genes, $41,506; Tamminga, Carol, NIH, Bipolar & Schizophrenia Consortium for Parsing Endophenotypes, $886,102.
Timmerman, Robert, NIH/American Coll. of Radiology, Radiation Therapy Oncology Group (RTOG), $2,800; Trivedi, Madhukar, NIH, Mood Disorders Clinical Intervention Training Program, $359,547; Varley, Alan, NIH, Interactions of Endotoxin With Plasma and Cells, $42,547; Wakeland, Edward, NIH, Genetic Dissection of SLE Pathogenesis, $1,598,976; Ward Ober, E. Sally, NIH, Mechanistic Studies of FcRn Inhibitors for Treatment of IgG-Mediated Diseases, $341,946.
Weakley, David, NIH/JAEB Ctr. for Health Research, Pediatric Eye Disease Investigator Group: Amblyopia Treatment Study, $628; Winick, Naomi, NIH/National Childhood Cancer Fndtn., COG Chair Grant PCR; #1233, $113,573; Winick, Naomi, NIH/National Childhood Cancer Fndtn., COG Chair Grant; Chirmeric Antibody — ARRA Stimulus Funding, $45,999; Winick, Naomi, NIH/National Childhood Cancer Fndtn., COG Phase 1 Pilot Consortium; #19396 — ARRA Stimulus Funding, $45,999; Winick, Naomi, NIH/National Childhood Cancer Fndtn., COG Phase 1 Pilot Consortium PCR; #1021, $3,000.
Zimmern, Philippe, NIH/New England Research Inst., Urinary Incontinence Treatment Network (UITN); Site 171, $3,000; Zou, Hui, NIH, Investigate Downstream Mechanisms and Upstream Regulation of Acetyltransferase San, $295,317.
Chen, Zhijian, Welch Fndtn., Biochemical Mechanism of NFkB Inhibition by Deubiquitination Enzymes, $90,000; Chuang, David, Welch Fndtn., Mitochondrial Signaling by Reversible Phosphorylation, $70,000; Corbin, Ian, American Gastroenterological Assn., Novel Lipoprotein-Based Nanoparticle Platform for Enhanced Targeting, Detection and Treatment of Hepatocellular Carcinoma Using Local Regional Strategies, $60,000; DeMartino, George, Welch Fndtn., Mechanisms and Regulation of 26S Proteasome Assembly and Activation, $50,000; Frohman, Elliot, Cleveland Clinic Fndtn., Validation Study of Diffusion Tensor Imaging as Physiologically Relevant Biomarker of Brain Tissue Integrity, $137,815.
Hsieh, Jenny, Welch Fndtn., Chemical Regulation of Adult Hippocampal Neurogenesis, $50,000; Jiang, Youxing, Welch Fndtn., Structural and Functional Studies of RCK-Regulated Potassium Channel, $10,000; Li, Wen-Hong, Human Frontier Science Program, Advancing STED-based Photoactivation to Study Synaptic Physiology at Nanoscale, $116,666; Ranganathan, Rama (F. Poelwijk, fellow), Helen Hay Whitney Fndtn., Evolutionary Dynamics and Design of Natural Proteins, $45,500; Thomas, Philip, Cystic Fibrosis Fndtn., Development of Methods and Reagents for Assessing CFTR Folding, $292,964.
Ward Ober, E. Sally, Medimmune LLC, Fate of Antibody Antigen Complexes Upon Endocytosis and Role of FcRn, $216,971; White, Michael, Welch Fndtn., Analysis of Functional Significance of Complex Protein/Protein Interactions, $10,000; Wolfe, Gil, Myasthenia Gravis Fndtn./Johns Hopkins Univ., Genome-Wide Assn. Study in Myasthenia Gravis, $16,700; Zou, Hui, Welch Fndtn., In-Vivo Assay to Determine Separase Activity in Across the Cell Cycle, $50,000.
Industry-Sponsored Awards, dollar amounts not available
Diaz-Arrastia, R., A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dosage Study to Evaluate the Efficacy and Safety of Armodafinil (50, 150 and 250 mg/day) as Treatment for Patients With Excessive Sleepiness Associated with Mild or Moderate Closed Traumatic Brain Injury; Gumbo, T., Population Pharmacokinetic Analysis of Micafungin in Overweight, Obese and Extremely Obese Patients; Holper, E., Prospective, Multi-Center, Randomized, Double-Blind Trial to Assess the Effectiveness and Safety of 12 vs. 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-Eluting Stent or Bare Metal Stent Placement for the Treatment of Coronary Artery Lesions.
Jain, M., A Phase 2b Multicenter, Randomized, Comparative Trial of UK-453,061 vs. Etravirine in Combination With Darunavir/Ritonavir and a Nucleotide/Nucleoside Reverse Transcriptase Inhibitor for the Treatment of Antiretroviral Experienced HIV-1 Infected Subjects With Evidence of NNRTI Resistant HIV-1; Jain, M., A Phase 2B/3 Open-Label Rollover Study for Subjects Discontinuing From the UK-453,061 Protocols for the Treatment of HIV-1 Infected Subjects; Jain, M., A Randomized, Multicenter, Single Blinded, Parallel Study of the Safety of 100 mg and 200 mg Oseltamivir Administered Intravenously for the Treatment of Influenza in Patients Aged ≥ 13 Years; Torres, F., A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose-Ranging Study of Cicletanine in Subjects With Pulmonary Arterial Hypertension.
Toto, R., A Multicenter, Open-Label, Randomized, Parallel Group, Dose-Ranging, Pharmacodynamic Phase II Trial to Determine the Effects of Bardoxolone Methyl (RTA 402, Amorphous Dispersion) on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease (eGFR 1545 mL/min/1.73m2); Verma, U., A Randomized, Double-Blind, Multicenter Phase III Study Comparing Everolimus (RAD001) Plus Best Supportive Care vs. Placebo Plus Best Supportive Care in Patients With Advanced Gastric Cancer After Progression on Prior Systemic Chemotherapy; Vusirikala, M., A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of the Safety, Tolerability and Ability of CMX001 to Prevent or Control CMV Infection in R+ Hematopoietic Stem Cell Transplant Recipients.